Dashboard
Manage Tickers

BIIB


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bio-thera-solutions-biogen-publish-phase-3-clinical-trial-data-for-tofidence-an-approved-biosimilar-referencing-tocilizumab-in-arthritis-research--therapy
Bio-Thera Solutions, Biogen Publish Phase ...
09/11/2024 12:12:34

Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen, the publication in the journal Arthritis Research &...

Core News & Articles
C4 Therapeutics Has Delivered A Second Dev...
09/10/2024 11:07:03

zepbound-and-mounjaro-maker-eli-illy-has-a-new-cfo-as-it-navigates-regulatory-challenges-what-you-should-know
Zepbound And Mounjaro Maker Eli Illy Has A...
09/10/2024 03:00:59

Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediate...

bernie-sanders-says-if-youre-poor-in-america-youll-live-10-15-years-less-anybody-else-see-a-problem-with-that
Bernie Sanders Says If You're Poor In Amer...
09/10/2024 02:12:36

cantor-fitzgerald-reiterates-overweight-on-biogen-maintains-292-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:28:53

Cantor Fitzgerald analyst Eric Schmidt reiterates Biogen (NASDAQ:BIIB) with a Overweight and maintains $292 price target.

biogeneisais-leqembi-brings-hope-to-early-alzheimers-patients-amid-logistical-challenges
Biogen/Eisai's Leqembi Brings Hope To Earl...
09/09/2024 14:12:06

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highligh...

biogens-higher-dose-spinraza-shows-to-slow-neurodegeneration-faster-in-infants-with-rare-neuromuscular-disorder
Biogen's Higher Dose Spinraza Shows To Slo...
09/04/2024 14:43:28

Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor ...

key-takeaways-from-biogen-analyst-ratings
Key Takeaways From Biogen Analyst Ratings
09/04/2024 13:00:55

biogen-announces-data-for-higher-dose-nusinersen-in-infants-with-spinal-muscular-atrophy
Biogen Announces Data for Higher Dose Nusi...
09/04/2024 11:33:42

Biogen Inc. (NASDAQ:BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study...

needham-reiterates-buy-on-biogen-maintains-285-price-target
Needham Reiterates Buy on Biogen, Maintain...
09/04/2024 10:25:26

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.

eli-lilly-is-the-nvidia-of-weight-loss-and-glp-1-space-says-roundhill-investments-ceo-emphasizes-market-leadership-and-growth-potential-of-zepbound-maker
Eli Lilly Is The Nvidia Of Weight Loss And...
08/28/2024 08:21:26

Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.

chinese-e-commerce-giant-drops-35-in-2-days-but-analysts-see-92-upside-potential
Chinese E-Commerce Giant Drops 35% In 2 Da...
08/27/2024 20:56:47

PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets r...

eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safety
Eli Lilly's Alzheimer's Drug Faces UK Agen...
08/26/2024 12:45:22

The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent ...

biogens-alzheimers-drug-secures-uk-approval-but-an-independent-agency-does-not-recommend-reimbursement
Biogen's Alzheimer's Drug Secures UK Appro...
08/22/2024 17:45:50

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild co...

eisai-and-biogens-alzheimers-drug-leqembi-receives-first-european-approval-in-great-britain
Eisai and Biogen's Alzheimer's Drug Leqemb...
08/22/2024 09:13:37

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...

cracking-the-code-understanding-analyst-reviews-for-biogen
Cracking The Code: Understanding Analyst R...
08/19/2024 13:00:41

needham-reiterates-buy-on-biogen-maintains-285-price-target
Needham Reiterates Buy on Biogen, Maintain...
08/19/2024 09:31:20

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.

how-is-the-market-feeling-about-biogen
How Is The Market Feeling About Biogen?
08/09/2024 19:45:24

mizuho-maintains-outperform-on-biogen-lowers-price-target-to-251
Mizuho Maintains Outperform on Biogen, Low...
08/06/2024 11:19:51

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $277 to $251.

truist-securities-reiterates-buy-on-biogen-lowers-price-target-to-302
Truist Securities Reiterates Buy on Biogen...
08/05/2024 13:43:51

Truist Securities analyst Srikripa Devarakonda reiterates Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION